Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine, Cambridge, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.
Genet Med. 2017 Oct;19(10):1096-1104. doi: 10.1038/gim.2017.14. Epub 2017 Mar 16.
Data sharing through ClinVar offers a unique opportunity to identify interpretation differences between laboratories. As part of a ClinGen initiative, four clinical laboratories (Ambry, GeneDx, Partners Healthcare Laboratory for Molecular Medicine, and University of Chicago Genetic Services Laboratory) collaborated to identify the basis of interpretation differences and to investigate if data sharing and reassessment resolve interpretation differences by analyzing a subset of variants.
ClinVar variants with submissions from at least two of the four participating laboratories were compared. For a subset of identified differences, laboratories documented the basis for discordance, shared internal data, independently reassessed with the American College of Medical Genetics and Genomics-Association for Molecular Pathology (ACMG-AMP) guidelines, and then compared interpretations.
At least two of the participating laboratories interpreted 6,169 variants in ClinVar, of which 88.3% were initially concordant. Laboratories reassessed 242/724 initially discordant variants, of which 87.2% (211) were resolved by reassessment with current criteria and/or internal data sharing; 12.8% (31) of reassessed variants remained discordant owing to differences in the application of the ACMG-AMP guidelines.
Participating laboratories increased their overall concordance from 88.3 to 91.7%, indicating that sharing variant interpretations in ClinVar-thereby allowing identification of differences and motivation to resolve those differences-is critical to moving toward more consistent variant interpretations.Genet Med advance online publication 09 March 2017.
通过 ClinVar 进行数据共享为鉴定实验室间的解读差异提供了独特的机会。作为 ClinGen 计划的一部分,四个临床实验室(Ambry、GeneDx、Partners Healthcare 分子医学实验室和芝加哥大学遗传服务实验室)合作,通过分析一部分变体来确定解读差异的基础,并调查数据共享和重新评估是否可以解决解读差异。
对至少有两个参与实验室提交的 ClinVar 变体进行了比较。对于确定的差异子集,实验室记录了不一致的依据,共享内部数据,独立地根据美国医学遗传学学院-分子病理学协会(ACMG-AMP)指南重新评估,然后比较解读结果。
至少有两个参与实验室在 ClinVar 中解读了 6169 个变体,其中 88.3%的变体最初是一致的。实验室重新评估了 724 个最初不一致的变体中的 242 个,其中 87.2%(211 个)通过重新评估当前标准和/或内部数据共享得到解决;12.8%(31 个)重新评估的变体由于 ACMG-AMP 指南的应用差异仍然不一致。
参与实验室的总体一致性从 88.3%提高到 91.7%,这表明在 ClinVar 中共享变体解读——从而可以识别差异并解决这些差异——对于朝着更一致的变体解读方向发展至关重要。遗传医学在线发表 2017 年 3 月 9 日。